All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-MV-01LX388 | Anti-MAGE1 (M3H67) h(41BB-CD3ζ) CAR, pMMLV | Human | M3H67 | human | scFv-41BB-CD3ζ | Recombinant Moloney murine leukemia virus (MMLV) retroviral vector | T cell | ||
CAR-MV-01LX389 | Anti-MAGE1 (M/YC-15) h(41BB-CD3ζ) CAR, pMMLV | Human | M/YC-15 | human | scFv-41BB-CD3ζ | Recombinant Moloney murine leukemia virus (MMLV) retroviral vector | T cell | ||
CAR-MV-01LX390 | Anti-MAGE1 (Hyb3) h(41BB-CD3ζ) CAR, pMMLV | Human | Hyb3 | Human | scFv-41BB-CD3ζ | Recombinant Moloney murine leukemia virus (MMLV) retroviral vector | T cell | ||
CAR-SB-02LX140 | Anti-MAGE1 (M3H67) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | Human | M3H67 | Human | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
CAR-SB-02LX141 | Anti-MAGE1 (M/YC-15) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | Human | M/YC-15 | Human | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
CAR-SB-02LX142 | Anti-MAGE1 (Hyb3) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | Human | Hyb3 | Human | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
CAR-SB-02LX382 | Anti-MAGE1 (M3H67) h(CD28-OX40-CD3ζ) CAR, pSBCAR1 | Human | M3H67 | Human | scFv-CD28-OX40-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
CAR-SB-02LX383 | Anti-MAGE1 (M/YC-15) h(CD28-OX40-CD3ζ) CAR, pSBCAR1 | Human | M/YC-15 | Human | scFv-CD28-OX40-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
CAR-SB-02LX384 | Anti-MAGE1 (Hyb3) h(CD28-OX40-CD3ζ) CAR, pSBCAR1 | Human | Hyb3 | Human | scFv-CD28-OX40-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
CAR-SB-02LX624 | Anti-MAGE1 (M3H67) h(ICOS-4-1BB-CD3ζ) CAR, pSBCAR1 | Human | M3H67 | Human | scFv-ICOS-4-1BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
CAR-SB-02LX625 | Anti-MAGE1 (M/YC-15) h(ICOS-4-1BB-CD3ζ) CAR, pSBCAR1 | Human | M/YC-15 | Human | scFv-ICOS-4-1BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
CAR-SB-02LX626 | Anti-MAGE1 (Hyb3) h(ICOS-4-1BB-CD3ζ) CAR, pSBCAR1 | Human | Hyb3 | Human | scFv-ICOS-4-1BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
XS-1022-LX763 | Anti-MAGE1 (X10X595) h(CD28-CD3ζ) CAR, piggyBac vector system | Human | X10X595 | human | scFv-CD28-CD3ζ | piggyBac transposon | T cell | ||
XS-1022-LX764 | Anti-MAGE1 (X10X596) h(CD28-CD3ζ) CAR, piggyBac vector system | Human | X10X596 | human | scFv-CD28-CD3ζ | piggyBac transposon | T cell | ||
XS-1022-LX765 | Anti-MAGE1 (X10X597) h(CD28-CD3ζ) CAR, piggyBac vector system | Human | X10X597 | Human | scFv-CD28-CD3ζ | piggyBac transposon | T cell | ||
XS-1022-LX1417 | Anti-MAGE1 (X10X595) h(41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X595 | human | scFv-41BB-CD3ζ | piggyBac transposon | T cell | ||
XS-1022-LX1418 | Anti-MAGE1 (X10X596) h(41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X596 | human | scFv-41BB-CD3ζ | piggyBac transposon | T cell | ||
XS-1022-LX1419 | Anti-MAGE1 (X10X597) h(41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X597 | Human | scFv-41BB-CD3ζ | piggyBac transposon | T cell | ||
XS-1022-LX2071 | Anti-MAGE1 (X10X595) h(CD28-41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X595 | human | scFv-CD28-41BB-CD3ζ | piggyBac transposon | T cell | ||
XS-1022-LX2072 | Anti-MAGE1 (X10X596) h(CD28-41BB-CD3ζ) CAR, piggyBac vector system | Human | X10X596 | human | scFv-CD28-41BB-CD3ζ | piggyBac transposon | T cell | ||
XS-0823-LX76 | Anti-hMAGE1 (B3) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector | Human | B3 | Adenoviral vectors |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION